Schlam, Ilana
Church, Sarah E.
Hether, Tyler D.
Chaldekas, Krysta
Hudson, Briana M.
White, Andrew M.
Maisonet, Emily
Harris, Brent T.
Swain, Sandra M. http://orcid.org/0000-0002-1320-3830
Funding for this research was provided by:
breast cancer research foundation (BCRF-20-156 2020-2021, BCRF-19-156 2019-2020)
national cancer institute (grant P30 CA051008)
Article History
Received: 14 June 2021
Accepted: 10 October 2021
First Online: 27 November 2021
Declarations
:
: Archival samples were selected through Georgetown University Hospital Institutional Review Board (IRB) approved protocols (1992-048, 2007-345 and Pro00000007).
: Schlam: none. S.E. Church: NanoString Technologies, Inc. K. Chaldekas: none. B.M. Hudson: NanoString Technologies, Inc. A.M. White: NanoString Technologies, Inc. E. Maisonet: none. T. Hether: NanoString Technologies, Inc. B.T. Harris: none. S.M. Swain: Member, independent data monitoring committee; Consulting Athenex, Daiichi-Sankyo, Natera, AstraZeneca, Exact Sciences (Genomic Health), Bejing Medical Foundation, Genentech/Roche, Merck, Lilly Pharmaceuticals. Non-promotional speaking, third-party writing assistance: Genentech/Roche. Research to Institution; Kailos Genetics.